A randomized controlled trial published in the Lancet, evaluated the use of alemtuzumab for patients with relapsing-remitting multiple sclerosis.  The monoclonal antibody is approved to treat leukemia and has been used off-label for multiple sclerosis.  The study compared alemtuzumab with interferon beta 1a, a widely used first line therapy for multiple sclerosis and concluded that alemtuzumab could reduce relapse rates and disability. What other treatment options are currently available for relapsing-remitting multiple sclerosis?

For more information, please see the Lancet.